HOME >> MEDICINE >> NEWS
Media undermine efforts to tackle nicotine addiction

Inaccurate media reports surrounding the safety of new smoking cessation drugs are undermining the treatment of nicotine addiction, according to an editorial in this week's BMJ.

Professor Linda Ferry presents two scenarios that illustrate the struggle between the press and medical experts to investigate and report concerns about the safety of new drugs for smoking cessation, and the effect this struggle has on reported attempts to quit smoking.

In the United Kingdom, bupropion hydrochloride (Zyban) was heralded by the media as a wonder drug when it was released in 2000. Not surprisingly, smokers queued up in waiting rooms, expecting their tobacco addiction to be vanish with this new pill.

The public enthusiasm changed abruptly in February 2001 when a London newspaper profiled a few dramatic reports of deaths in smokers using bupropion. Although experts remain convinced of the safety of bupropion, the demand for treatment has declined.

A similar shift in public opinion followed media reports in the United States about an increased risk of heart attack associated with nicotine patches. A subsequent trial showed that patches were safe to use, specifically in patients with heart disease, but many smokers still believe the original media messages that if I use a patch and smoke even one cigarette, I might have a heart attack.

Clinicians should give clear messages to their patients that it is much safer to use either of these drugs to help their attempts to quit than to continue smoking, says the author. Unfortunately, much damage has been done.

Tobacco treatment specialists and public health agencies need to refute the inaccuracies of the media and present a clear picture of the enormous problem of preventable disability and the 120,000 tobacco related deaths a year from the 13 million smokers in the United Kingdom, she concludes.


'"/>

Contact: Emma Wilkinson
ewilkinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
6-Jun-2002


Page: 1

Related medicine news :

1. Media update: GSA underscores hottest meeting topics
2. Media invitation first annual EDCTP Forum
3. Media invitation - European Society of Cardiology Congress 2004
4. Media invitation: The Movement Disorder Societys 7th International Congress
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Review of preliminary observations concludes the Mayo Clinic Natl Conf on Medicine and the Media
7. Media focus on endostatin helped -- not hurt --
8. Media advisory: Mayo Clinic study finds infliximab safe and beneficial for Crohns disease
9. Media coverage of new drugs is often misleading
10. Media advisory: Mayo Clinic study shows increased incidence of migraines in women
11. American Heart Association Media Advisory: Cholesterol Lowering Margarines

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Media undermine efforts tackle nicotine addiction

(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The Daily ... to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the use ... the new study showed that harvesting stem cell-rich bone marrow from the hip, known ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular North ... NA’s cyclotron sites and research and development facilities. , “We are excited ... a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Hub International Insurance ... Williams has joined its growing California employee benefits division. Mr. Williams will ... his clients. Mr. Williams will be joining the newly integrated Northern California employee ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Government Programs, with accountability for overall performance of the company’s Medicare and Federal ... focus of Cambia’s strategy to deliver better health for members. In this role, ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... provider of medical information, risk management and investigative services, has introduced a ... toward focused, expert information solutions that improve business outcomes for its customers. ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, Inc. ... a strategic collaboration to discover and develop antisense ... new collaboration builds on a broad existing relationship ... approach in these therapeutic areas using novel RNA-targeted ... use of its antisense technology to diseases of ...
(Date:7/31/2015)... N.C. , July 31, 2015  In today,s ... customers who are increasingly mobile, increasingly connected, and increasingly ... growing variety of customer interaction channels and tools is ... including social media. According to research ... over the counter (OTC) segment in a call center ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
Cached News: